• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Precipio Inc.

    9/22/25 4:33:20 PM ET
    $PRPO
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $PRPO alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    Precipio, Inc.

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)


    74019L107

    (CUSIP Number)


    09/19/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    74019L107


    1Names of Reporting Persons

    Leviticus Partners LP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    130,000.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    130,000.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    130,000.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    8.0 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Precipio, Inc.
    (b)Address of issuer's principal executive offices:

    12325 EMMET ST, OMAHA, NEBRASKA, 68164
    Item 2. 
    (a)Name of person filing:

    Adam M Hutt
    (b)Address or principal business office or, if none, residence:

    32 Old Mill Road Great Neck, NY 11023
    (c)Citizenship:

    United States
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP No.:

    74019L107
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    130,000.00
    (b)Percent of class:

    8.0%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    130,000.00

     (ii) Shared power to vote or to direct the vote:

    0

     (iii) Sole power to dispose or to direct the disposition of:

    130,000.00

     (iv) Shared power to dispose or to direct the disposition of:

    0

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Leviticus Partners LP
     
    Signature:Adam M Hutt
    Name/Title:Managing Member
    Date:09/22/2025
    Get the next $PRPO alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PRPO

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PRPO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Sandberg Richard A bought $13,986 worth of shares (1,399 units at $10.00) (SEC Form 4)

    4 - Precipio, Inc. (0001043961) (Issuer)

    5/30/25 4:31:15 PM ET
    $PRPO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Director Sandberg Richard A bought $990 worth of shares (101 units at $9.80) (SEC Form 4)

    4 - Precipio, Inc. (0001043961) (Issuer)

    5/28/25 4:37:44 PM ET
    $PRPO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Director Sandberg Richard A bought $4,665 worth of shares (500 units at $9.33) (SEC Form 4)

    4 - Precipio, Inc. (0001043961) (Issuer)

    5/27/25 4:05:45 PM ET
    $PRPO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $PRPO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Precipio Terminates Its ATM

    NEW HAVEN, Conn., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), has terminated its ATM (At-The-Market) instrument with investment bank Alliance Global Partners (AGP). "Our Company is in a much stronger position today than it was when we entered into this structure. With our elimination of negative cash flow from operations, and our recent increases of our cash balance, we now have confidence that we no longer have to rely on a tool like this for capital raises for the Company," said Ilan Danieli, Precipio's CEO. "Management is committed to creating shareholder value, and this termination is one more step in that direction." About Pr

    9/2/25 10:00:00 AM ET
    $PRPO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Precipio Announces its Q2-2025 Financial Results

    NEW HAVEN, Conn., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), filed its 10-Q report today. The following are the highlights of the Company's financial performance and outlook for 2025. "Yet another quarter of revenue growth in both company divisions, along with overall gross margin improvement, has led to an improved cash performance for the Company. With the remaining repayment of the Change Healthcare loan to be completed by the end of the year, and continued strength in both revenue and margin growth, management believes that the Company is on track to end the year as a cash flow positive business, and with a debt-free, strong ba

    8/13/25 5:00:00 PM ET
    $PRPO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Precipio Announces Q2-2025 Shareholder Update Call

    NEW HAVEN, Conn., July 31, 2025 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), will be hosting its Q2-2025 corporate update call on August 14th, 2025 at 5:00 PM ET. The call will include updates on all of the company's current core businesses. The conference call may be accessed by calling 800.717.1738. All callers should ask for the Precipio conference call. Listeners interested in submitting questions in advance should email their questions to [email protected] and management will do its best to address those questions during the call. A replay of the call will be available approximately 24 hours after the call and may be accessed via the

    7/31/25 4:30:00 PM ET
    $PRPO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $PRPO
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by Precipio Inc.

    SCHEDULE 13G - Precipio, Inc. (0001043961) (Subject)

    9/22/25 4:33:20 PM ET
    $PRPO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Precipio Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - Precipio, Inc. (0001043961) (Filer)

    9/3/25 4:00:34 PM ET
    $PRPO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Precipio Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Precipio, Inc. (0001043961) (Filer)

    8/18/25 5:01:19 PM ET
    $PRPO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $PRPO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Laporte Kathleen sold $123,409 worth of shares (6,152 units at $20.06), decreasing direct ownership by 50% to 6,151 units (SEC Form 4)

    4 - Precipio, Inc. (0001043961) (Issuer)

    9/10/25 4:03:55 PM ET
    $PRPO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: Director Cossman Jeffrey was granted 710 shares, increasing direct ownership by 5% to 14,743 units (SEC Form 4)

    4/A - Precipio, Inc. (0001043961) (Issuer)

    7/18/25 6:28:20 PM ET
    $PRPO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Director Andrews Ronald Asbury was granted 676 shares, increasing direct ownership by 5% to 15,228 units (SEC Form 4)

    4 - Precipio, Inc. (0001043961) (Issuer)

    7/18/25 4:36:53 PM ET
    $PRPO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $PRPO
    Financials

    Live finance-specific insights

    View All

    Precipio Terminates Its ATM

    NEW HAVEN, Conn., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), has terminated its ATM (At-The-Market) instrument with investment bank Alliance Global Partners (AGP). "Our Company is in a much stronger position today than it was when we entered into this structure. With our elimination of negative cash flow from operations, and our recent increases of our cash balance, we now have confidence that we no longer have to rely on a tool like this for capital raises for the Company," said Ilan Danieli, Precipio's CEO. "Management is committed to creating shareholder value, and this termination is one more step in that direction." About Pr

    9/2/25 10:00:00 AM ET
    $PRPO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Precipio Announces its Q2-2025 Financial Results

    NEW HAVEN, Conn., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), filed its 10-Q report today. The following are the highlights of the Company's financial performance and outlook for 2025. "Yet another quarter of revenue growth in both company divisions, along with overall gross margin improvement, has led to an improved cash performance for the Company. With the remaining repayment of the Change Healthcare loan to be completed by the end of the year, and continued strength in both revenue and margin growth, management believes that the Company is on track to end the year as a cash flow positive business, and with a debt-free, strong ba

    8/13/25 5:00:00 PM ET
    $PRPO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Precipio Announces Q2-2025 Shareholder Update Call

    NEW HAVEN, Conn., July 31, 2025 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), will be hosting its Q2-2025 corporate update call on August 14th, 2025 at 5:00 PM ET. The call will include updates on all of the company's current core businesses. The conference call may be accessed by calling 800.717.1738. All callers should ask for the Precipio conference call. Listeners interested in submitting questions in advance should email their questions to [email protected] and management will do its best to address those questions during the call. A replay of the call will be available approximately 24 hours after the call and may be accessed via the

    7/31/25 4:30:00 PM ET
    $PRPO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $PRPO
    Leadership Updates

    Live Leadership Updates

    View All

    Precipio Inc. Announces the Resignation of its Chief Financial Officer and Appointment of Interim CFO

    NEW HAVEN, Conn., March 21, 2022 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), today announced that Mr. Carl Iberger, Precipio's CFO for the past five years, is resigning as the Chief Financial Officer effective as of today, March 21st, 2022. Mr. Iberger wishes to spend more time with his family and therefore has made the decision to step down from his role as CFO. Matt Gage, who currently serves as Director of Financial Reporting and Analysis has been promoted to Interim Chief Financial Officer of the Company effective immediately. Mr. Gage joined Precipio following its acquisition of Transgenomic in July of 2017. He has worked closely with Mr. Ib

    3/21/22 5:00:00 PM ET
    $PRPO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    89bio Announces Appointment of Kathy LaPorte to its Board of Directors

    SAN FRANCISCO, Nov. 03, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. (NASDAQ:ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced the appointment of Kathy LaPorte to its Board of Directors, effective immediately. Ms. LaPorte brings deep expertise and valuable experience in the industry to the Company. "It is a pleasure to welcome Kathy, an esteemed industry leader, to our Board of Directors," said Rohan Palekar, Chief Executive Officer of 89bio. "Kathy has a strong track record for enhancing operational capabilities to drive growth. Her extensive experien

    11/3/21 8:00:00 AM ET
    $BOLT
    $ETNB
    $PRPO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Mr. Richard Sandberg is appointed Chairman of Precipio’s Board of Directors

    NEW HAVEN, Conn., March 03, 2021 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announces the appointment of Mr. Richard Sandberg as Chairman of the Board of Directors. Dr. Douglas Fisher will step down as Chairman and maintain his role as a Director on the company’s board. Mr. Sandberg has been involved with Precipio since its inception and has acted in various advisory roles. in 2019 he joined the company’s Board of Directors and has been a significant contributor to helping the company formulate strategy and execute on its plans. Mr Sandberg is a seasoned diagnostics executive with a substantial track record in the field of diagnostics. As the f

    3/3/21 11:00:00 AM ET
    $PRPO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $PRPO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Precipio Inc.

    SC 13G - Precipio, Inc. (0001043961) (Subject)

    8/2/24 2:15:53 PM ET
    $PRPO
    Biotechnology: Laboratory Analytical Instruments
    Industrials